脂质体作为疫苗佐剂的研究进展(4)
| 第1页 |
参见附件。
[24] Shek P， Heath T. Immune response mediated by liposome-associated protein antigens. III. Immunogenicity of bovine serum albumin covalently coupled to vesicle surface. Immunology， 1983， 50(1)： 101–106.
[25] Bakouche O， Gerlier D. Enhancement of immunogenicity of tumour virus antigen by liposomes： the effect of lipid composition. Immunology， 1986， 58 (3)： 507–513.
[26] Douglas S. Watson， Aaron N. Endsley， Leaf Huang. Design considerations for liposomal vaccines： Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine， 2012， 30(13)： 2256-2272.
[27] Herzog C， Hartmann K， Kunzi V， Kursteiner O， Mischler R， Lazar H， et al. Eleven years of In？exal V-a virosomal adjuvanted in？uenza vaccine. Vaccine， 2009， 27 (33)： 4381–4387.
[28] Szoka Jr F， Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng， 1980， 9： 467–508.
[29] Bonifaz L， Bonnyay D， Mahnke K， Rivera M， Nussenzweig MC， Steinman RM. Ef？cient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med， 2002， 196 (12)： 1627–1638.
[30] Tacken PJ， de Vries IJ， Torensma R， Figdor CG. Dendritic-cell immunotherapy： from ex vivo loading to in vivo targeting. Nat Rev Immunol， 2007， 7(10)： 790–802.
[31] De haan A， Geerligs AJ， Auchshorn JP. et al. Mucosal immuno-adjuvant activity of liposomes： induction of systemic IgG and secretary IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes[J]. Vaccine， 1995， 13： 155-162.
(收稿日期：20131107)
您现在查看是摘要介绍页，详见PDF附件。